INT200796

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 2006
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 7
Total Number 7
Disease Relevance 3.22
Pain Relevance 0.18

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Epo) extracellular region (Epo)
Anatomy Link Frequency
neurons 3
tube 1
Plasma 1
Epo (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammatory response 19 96.16 Very High Very High Very High
cytokine 19 93.04 High High
long-term potentiation 14 50.00 Quite Low
anesthesia 9 44.72 Quite Low
metalloproteinase 3 34.88 Quite Low
Hippocampus 21 5.00 Very Low Very Low Very Low
depression 17 5.00 Very Low Very Low Very Low
Inflammation 16 5.00 Very Low Very Low Very Low
fibrosis 10 5.00 Very Low Very Low Very Low
cva 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Myelodysplastic Syndromes 124 99.44 Very High Very High Very High
Apoptosis 62 97.88 Very High Very High Very High
INFLAMMATION 35 96.16 Very High Very High Very High
Neurodegenerative Disease 10 95.48 Very High Very High Very High
Erythrocytosis 73 94.04 High High
Stroke 10 87.84 High High
Lifespan 6 86.68 High High
Diabetes Mellitus 1 86.28 High High
Injury 8 85.80 High High
Congenital Anomalies 20 84.88 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Reduction of synaptic vesicle priming and transmitter release in the EPO pre-treated neurons
Negative_regulation (Reduction) of EPO in neurons
1) Confidence 0.43 Published 2008 Journal BMC Biol Section Body Doc Link PMC2562991 Disease Relevance 0 Pain Relevance 0
Interestingly, bevacizumab abolished VEGF-induced tube formation, but not EPO-induced tube formation.
Negative_regulation (abolished) of EPO in tube
2) Confidence 0.42 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2981551 Disease Relevance 0.23 Pain Relevance 0
To assess the DNA dose appropriate to this aim, we first evaluated Epo plasmid doses of 2, 4 and 6 ?
Negative_regulation (evaluated) of Epo
3) Confidence 0.42 Published 2008 Journal Genet Vaccines Ther Section Body Doc Link PMC2276190 Disease Relevance 0.07 Pain Relevance 0
Plasma Epo levels were suppressed in JAK2 V617F recipients (Figure 1G), demonstrating that the erythropoiesis in these mice is autonomous, and not driven by overproduction of Epo.
Neg (not) Negative_regulation (suppressed) of Epo in Plasma
4) Confidence 0.37 Published 2006 Journal PLoS ONE Section Body Doc Link PMC1762384 Disease Relevance 0.55 Pain Relevance 0
Comparing the number of apoptotic neurons in the brains of rhEpo treated mice and vehicle treated controls with ECM we found a significant decrease in the rhEpo treated group (Figure 7).
Negative_regulation (decrease) of rhEpo in neurons associated with apoptosis
5) Confidence 0.37 Published 2008 Journal Malar J Section Body Doc Link PMC2257967 Disease Relevance 0.64 Pain Relevance 0
Studies of erythroid progenitors from PV patients demonstrated that Epo-independent erythroid maturation was impaired by a JAK2 inhibitor [12] and by siRNA knockdown of JAK2 [13].
Negative_regulation (impaired) of Epo associated with myelodysplastic syndromes
6) Confidence 0.36 Published 2006 Journal PLoS ONE Section Body Doc Link PMC1762384 Disease Relevance 0.94 Pain Relevance 0.05
As the Epo-R has been detected on neurons [29], the neuroprotective effect could be due to a direct effect of rhEpo.
Negative_regulation (effect) of rhEpo in neurons
7) Confidence 0.36 Published 2008 Journal Malar J Section Body Doc Link PMC2257967 Disease Relevance 0.80 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox